Matrilysin Expression in Different Stages of Colorectal Tumors

Colorectal Cancer Stage IV Clinical Trial

— MMP7  

Official title:

Matrilysin Expression in Different Stages of Colorectal Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01570452
• Other study ID #: andreapolistena1
• Status: Completed
• Phase: N/A
• First received: March 31, 2012
• Last updated: April 3, 2012
• Start date: September 2005
• Est. completion date: February 2012

Study information

• Verified date: March 2012
• Source: University of Roma La Sapienza
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: Ethics Committee
• Study type: Observational

Clinical Trial Summary

Matrix metalloproteinases (MMPs) have been shown to be involved in cancer biology. Significant expression of MMP-7 (matrilysin) in colorectal cancer is mainly associated with metastatic disease even though it is expressed in most tumor states. Our purpose is to analyse MMP-7 in bowel and lymph nodes of different tumor stages and to evaluate its expression as a potential biomarker of cancer disease in patients surgically treated for benign and malignant colorectal tumors. Tumoral tissue, lymph nodes and serum samples from recruited Patients plus serum samples from healthy volunteers are analysed for matrilysin expression by histology, immunohistochemistry, ELISA and Western blotting.

If Matrilysin increases with increasing dysplasia and cancer disease stage in tumor tissue as well as in the regional lymph nodes it might be used as a complement in investigating suspected locally advanced cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: February 2012
• Est. primary completion date: September 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 40 Years to 83 Years

Eligibility

Inclusion Criteria:

• benign colonic neoplasm not suitable for endoscopic treatment,

• malignant colonic neoplasm with indication to primary surgical treatment

Exclusion Criteria:

• neo-adjuvant radiotherapy,

• chemo-radiotherapy,

• language problems and withdrawal of consent

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Colorectal Cancer Stage 0
• Colorectal Cancer Stage I
• Colorectal Cancer Stage II
• Colorectal Cancer Stage III
• Colorectal Cancer Stage IV
• Colorectal Neoplasms

Intervention

Procedure:
• colonic or colorectal resection
standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection

Locations

Country	Name	City	State
Italy	Departement of Surgery Pietro Valdoni	Rome

Sponsors (1)

Lead Sponsor	Collaborator
University of Roma La Sapienza

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Mori M, Barnard GF, Mimori K, Ueo H, Akiyoshi T, Sugimachi K. Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer. 1995 Mar 15;75(6 Suppl):1516-9. — View Citation